Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Regimen-stratified genomics identifies candidate markers of benefit and resistance in adult T-cell leukemia/lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXiaoyi ZhangKSKimberly Seymour

Discussion

Loading...

Member takes

Overview

Integration of genomic data shows biomarkers and resistance in adult T-cell leukemia, indicating personalized treatment strategies.

Key Points

  • The study aims to identify biomarkers predicting response to therapy in adult T-cell leukemia/lymphoma.
  • Analyzed next-generation sequencing data from 47 ATLL patients
  • Classified therapies into regimen categories
  • Defined treatment responses as CR, PR, SD, PD, and Death
  • Identified 6 candidate biomarkers associated with treatment benefit and resistance
  • Notable genes include DIS3, IRF4, DNMT3A, ARID1B, and BRCA1
  • Found significant associations between biomarkers and progression-free survival (PFS).

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d56dhttps://doi.org/10.1182/blood-2025-7059
View Full Paper
Ask AI
Bookmark
Share